Geographic Atrophy

November 8th 2023

Caroline Baumal, Chief Medical Officer at Apellis, spoke with Ophthalmology Times on the GALE extension study of pegcetacoplan for geographic atrophy, and shared insights on her career transition, emphasizing the significance of mentorship and a passion for one’s work at this year's American Academy of Ophthalmology meeting in San Francisco.

November 7th 2023

This retrospective, multicenter, observational study examined Japanese patients with GA to determine the clinical characteristics and GA progression rate associated with AMD in an Asian population.

November 4th 2023

Results showed that IZERVAY met the primary objective of reducing the rate of geographic atrophy (GA) growth in patients treated monthly compared to sham-treated patients

November 3rd 2023

The purpose of this investigation was 2-fold: to estimate the costs of treating GA with pegcetacoplan and to identify possible utility measures to compare treatments for GA.